Telemedicine early medical abortion at home: evaluation

Footnotes

1 WP4 utilised findings from an ongoing project conducted by one of the co-investigators (Nicola Boydell), undertaken as part of, and funded by, a THIS (The Healthcare Improvement Studies) Institute fellowship.

2 See Effectiveness, safety and acceptability of no-test abortion (termination of pregnancy) provided via telemedicine: a national cohort study

3 SACP March 2020 guidance

4 See Abortion – Approval extension for Mifepristone to be taken at home

5 See Public Health Scotland Termination of pregnancy statistics year ending 2021

6 See Abortion – Covid-19 – Approval for Mifepristone to be taken at home and other contingency measures guidance

7 See Abortion – improvement to existing services – approval for Misoprostol to be taken at home

8 See Royal College of Obstetricians & Gynaecologists – Coronavirus (COVID-19) infection and abortion care

9 See World Health Organization (WHO). Abortion care guideline, 2022

10 See NICE Abortion care guidance, 2019

11 See Telemedicine medical abortion COVID at home under 12 weeks’ gestation: a prospective observational cohort study during the -19 pandemic; Adherence to treatment and prevalence of side effects when medical abortion is delivered via telemedicine: a prospective observational cohort study during COVID-19; Women's experiences of a telemedicine abortion service (up to 12 weeks) implemented during the coronavirus (COVID-19) pandemic: a qualitative evaluation; A qualitative study of abortion care providers perspectives on telemedicine medical abortion provision in the context of COVID-19

12 Effectiveness, safety and acceptability of no-test medical abortion (termination of pregnancy) provided via telemedicine: a national cohort study. BJOG

13 See Client satisfaction and experience of telemedicine and home use of mifepristone and misoprostol for abortion up to 10 weeks' gestation at British Pregnancy Advisory Service: A cross-sectional evaluation; Acceptability of no-test medical abortion provided via telemedicine during Covid-19: analysis of patient-reported outcomes

14 See Consultation on Future Arrangements for Early Medical Abortions at Home responses

15 See British Medical Journal Patient and Public Involvement (PPI) in abortion research: an exploratory survey

16 See Medical abortion reporting of efficacy: the MARE guidelines - contraception, 2016

17 See Utility of a routine ultrasound for detection of ectopic pregnancies among women requesting abortion: a retrospective review. BMJ Sexual and Reproductive Health

18 See Effectiveness, safety and acceptability of no-test medical abortion (termination of pregnancy) provided via telemedicine: a national cohort study

19 Telemedicine medical abortion at home under 12 weeks’ gestation: a prospective observational cohort study during the COVID-19 pandemic

20 See RCOG Telemedicine cost-effectiveness working group. Early medical abortion by telemedicine in the United Kingdom: a costing analysis. BJOG, 2022

21 World Health Organization (WHO). Abortion care guidelines, 2022.

22 Abortion – improvement to existing services – approval for Misoprostol to be taken at home

23 Note this is in line with the level of choice already requested of Health Boards in the CMO letter of 9 December 2021